Literature DB >> 20717643

[Therapy of peripheral vessel stenosis and occlusion in patients with thromboangiitis obliterans].

T A Sandner1, C Degenhart, J Becker-Lienau, M F Reiser, M Treitl.   

Abstract

Vasculitis consists of a group of diseases characterized by an inflammatory process of the vessel wall. There is a wide variation in symptoms and almost any organ or tissue can be affected. Thromboangiitis obliterans (TAO; also known as Buerger's disease) is a special form of vasculitis with recurring inflammation and thrombosis of small and medium size arteries and veins of the hands and feet. To date the etiology still remains unclear but there is a strong association with the use of tobacco products. Ulcerations and gangrene of the extremities are common complications often resulting in the need for amputation of the extremity involved. Treatment of TAO includes both surgical and non-surgical methods but there is still no agreement concerning the optimal treatment strategy. In this contribution the advantages and disadvantages of different treatment options will be addressed and representative cases will be discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717643     DOI: 10.1007/s00117-010-2003-z

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  24 in total

1.  Immunological studies in thromboangitis obliterans (Buerger's disease).

Authors:  S M Gulati; K S Singh; T K Thusoo; K Saha
Journal:  J Surg Res       Date:  1979-11       Impact factor: 2.192

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.

Authors:  J N Fiessinger; M Schäfer
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

Review 4.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

5.  Immunological aspect of smoking in patients with thromboangitis obliterans.

Authors:  L Simić; L Pirnat
Journal:  Vasa       Date:  1985       Impact factor: 1.961

6.  Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience.

Authors:  T Sasajima; Y Kubo; M Inaba; K Goh; N Azuma
Journal:  Eur J Vasc Endovasc Surg       Date:  1997-02       Impact factor: 7.069

7.  Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss.

Authors:  Peter F Lawrence; Olivia I Lund; Juan Carlos Jimenez; Rehan Muttalib
Journal:  J Vasc Surg       Date:  2008-07       Impact factor: 4.268

8.  Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials.

Authors:  E A Hussein; A el Dorri
Journal:  Int Surg       Date:  1993 Jan-Mar

9.  Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group.

Authors: 
Journal:  Eur J Vasc Endovasc Surg       Date:  1998-04       Impact factor: 7.069

10.  Clinical and social consequences of Buerger disease.

Authors:  Takashi Ohta; Hiroyuki Ishioashi; Minoru Hosaka; Ikuo Sugimoto
Journal:  J Vasc Surg       Date:  2004-01       Impact factor: 4.268

View more
  1 in total

Review 1.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.